Hims & Hers Stock Falls 63.1% Year-to-Date, Expands Weight Management and Cancer Testing
Hims & Hers shares plunged 59.7% over three months and 63.1% year-to-date, trading at a forward 12-month price-to-sales ratio of 1.3X versus its five-year median of 2.7X. The company launched UK weight management and menopause care services, added multi-cancer testing and agreed to acquire Eucalyptus and YourBio Health.
1. Stock Performance & Valuation
Hims & Hers shares have declined 59.7% over the past three months and 63.1% year-to-date, reflecting significant underperformance in digital health. The stock trades at a forward 12-month price-to-sales ratio of 1.3X, well below its five-year median of 2.7X and the Medical sector average of 2.3X, with a current Value Score of C.
2. Specialty Care Platform Expansion
Over the past year, Hims & Hers broadened its direct-to-consumer platform by launching UK weight management and menopause care offerings, introducing innovative testosterone treatments, rolling out proactive lab testing, and integrating multi-cancer early detection through a partnership with GRAIL.
3. International Acquisitions
Hims & Hers agreed to acquire Eucalyptus and YourBio Health to strengthen its presence in Australia, Japan, Germany and the U.K. These acquisitions bring local regulatory expertise, proprietary technology and infrastructure to accelerate global expansion.
4. Technology and Diagnostics Investments
The company is investing heavily in AI, diagnostics and proprietary technologies, supported by leadership additions and capital raises. These initiatives aim to enhance personalization, scale its platform and improve end-to-end care experiences for long-term growth.